Payment overview · 2025
General Payments
$866.80
38 reported records · 20 companies
Healthcare provider profile · identity verified
Michael Bruce Bogdanovich, MD
Allopathic & Osteopathic Physicians|Family Medicine · CEDAR PARK, TX · NPI 1386609048
Verified facts
What the public records show
CMS Open Payments records show Michael Bruce Bogdanovich, MD received $866.80 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Paxlovid, Rybelsus, Synthroid, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Unithroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.60 | 16.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.84 | 11.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.21 | 9.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.68 | 8.8% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $55.12 | 6.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.00 | 6.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.38 | 5.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.67 | 4.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.54 | 4.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.09 | 3.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.73 | 3.8% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $28.71 | 3.3% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $24.52 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.95 | 2.6% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $22.01 | 2.5% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.81 | 2.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.52 | 2.1% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $15.56 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.01 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.85 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $842.28 | 37 |
| Entertainment | $24.52 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $111.37 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $104.61 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $78.21 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $76.68 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.77 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $55.12 | 3 | 2025 |
Source payment records
|
|||||
| AFINION 2 Normalized: afinion 2 |
Device | Abbott Laboratories | $53.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.07 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $35.54 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.73 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $28.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 172 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 104 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 16 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 75 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
172 | 29 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 403 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 70 |
| Metformin Hcl Er | Metformin Hcl | 228 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 183 | 46 |
| Farxiga | Dapagliflozin Propanediol | 172 | 29 |
| Irbesartan | Irbesartan | 172 | 44 |
| Lisinopril | Lisinopril | 170 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 26 |
| Losartan Potassium | Losartan Potassium | 142 | 40 |
| Alprazolam | Alprazolam | 135 | 31 |
| Gabapentin | Gabapentin | 122 | 23 |
| Jardiance | Empagliflozin | 104 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 30 |
| Trazodone Hcl | Trazodone Hcl | 100 | 22 |
| Ezetimibe | Ezetimibe | 98 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 21 |
| Omeprazole | Omeprazole | 79 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 22 |
| Synthroid | Levothyroxine Sodium | 75 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 20 |
| Allopurinol | Allopurinol | 67 | 18 |
| Simvastatin | Simvastatin | 66 | 16 |
| Metformin Hcl | Metformin Hcl | 65 | 15 |
| Tramadol Hcl | Tramadol Hcl | 63 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 17 |
| Bupropion Xl | Bupropion Hcl | 60 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 15 |
| Montelukast Sodium | Montelukast Sodium | 59 | 18 |
| Ozempic | Semaglutide | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 17 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Meloxicam | Meloxicam | 48 | 14 |
| Carisoprodol | Carisoprodol | 46 | suppressed |
| Carvedilol | Carvedilol | 46 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 43 | 11 |
| Furosemide | Furosemide | 42 | 11 |
| Eliquis | Apixaban | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Kerendia | Finerenone | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Unithroid | Levothyroxine Sodium | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Azithromycin | Azithromycin | 21 | 20 |
| Estradiol | Estradiol | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Euthyrox | Levothyroxine Sodium | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | 11 |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Mirtazapine | Mirtazapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $866.80 · 38 records | AstraZeneca Pharmaceuticals LP | AFINION 2, AIRSUPRA, Auvelity, EVENITY, FARXIGA, JARDIANCE, Jornay PM, Kerendia, Korlym, MOUNJARO, NFC-700, NURTEC ODT, OCT OPHTHALMOSCOPE, Ozempic, PANORAMIC OPHTHALMOSCOPE, PAXLOVID, Quviviq, REXULTI, Rybelsus, SYNTHROID, Senza, TRELEGY ELLIPTA, UBRELVY, UNITHROID, VRAYLAR, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error